4′,6-Dihydroxy-4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation

Journal of Pharmacological Sciences

Volumn 125, Issue 2, 2014, Pages 193-201

  Mi, Chunliu ^a   Ma, Juan ^a   Shi, Hui ^a   Li, Jing ^a   Wang, Fei ^a   Lee, Jung Joon ^a   Jin, Xuejun ^a  

^a YANBIAN UNIVERSITY   (China)

Author keywords

4 ,6 dihydroxy 4 methoxyisoaurone; Antitumor; HIF 1 ; Translation

Indexed keywords

4',6 DIHYDROXY 4 METHOXYISOAURONE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; 4',6-DIHYDROXY-4-METHOXYISOAURONE; EIF4EBP1 PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; SESQUITERPENE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL LINE; CELL HYPOXIA; CELL INVASION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENE REPRESSION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANOXIA; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRICHOSANTHES; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANOXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SESQUITERPENES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRICHOSANTHES;

EID: 84903955438     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13273FP     Document Type: Article

References (38)

1. Li SH, Shin DH, Chun YS, Lee MK, Kim MS, Park JW. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther. 2008;7:3729-3738.
2. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851-864.
3. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008;105:19579-19586.
4. Lou JJ, Chua YL, Chew EH, Gao J, Bushell M, Hagen T. Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One. 2010;5:e10522.
5. Lau CK, Yang ZF, Lam CT, Tam KH, Poon RT, Fan ST. Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun. 2006;348:1443-1448. (Pubitemid 44291359)
6. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
7. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1997;94:8104-8109. (Pubitemid 27343784)
8. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510-5514.
9. Yang DI, Chen SD, Yang YT, Ju TC, Xu JM, Hsu CY. Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1. Br J Pharmacol. 2004;141:988-996. (Pubitemid 38510082)
10. Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res. 2009;15:6128-6136.
11. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464-468. (Pubitemid 32335941)
12. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472. (Pubitemid 32335942)
13. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16:1466-1471. (Pubitemid 34686328)
14. Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci. 2008;33:526-534.
15. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732. (Pubitemid 37328811)
16. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270:1230-1237.
17. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541-1545. (Pubitemid 30183422)
18. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene. 2006;25:6373-6383. (Pubitemid 44582282)
19. Spriggs KA, Bushell M, Willis AE. Translational regulation of gene expression during conditions of cell stress. Mol Cell. 2010;40:228-237.
20. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 2004;64:8639-8642. (Pubitemid 39552077)
21. Dat NT, Jin X, Hong YS, Lee JJ. An isoaurone and other constituents from Trichosanthes kirilowii seeds inhibit hypoxia-inducible factor-1 and nuclear factor-kappaB. J Nat Prod. 2010;73:1167-1169.
22. Hervouet E, Cizkova A, Demont J, Vojtísková A, Pecina P, Franssen-van Hal NL, et al. HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis. 2008;29:1528-1537.
23. Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation. Eur J Pharmacol. 2008;592:41-47.
24. Jin HR, Jin SZ, Cai XF, Li D, Wu X, Nan JX, et al. Cryptopleurine targets NF-kappaB pathway, leading to inhibition of gene products associated with cell survival, proliferation, invasion, and angiogenesis. PLoS One. 2012;7:e40355.
25. Ma J, Liang H, Jin HR, Dat NT, Zhang SY, Jiang YZ, et al. Yangonin blocks tumor necrosis factor-alpha-induced nuclear factor-kappaB-dependent transcription by inhibiting the transactivation potential of the RelA/p65 subunit. J Pharmacol Sci. 2012;118:447-454.
26. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14:391-396. (Pubitemid 30131884)
27. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays. 2004;26:262-269. (Pubitemid 38325667)
28. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000;60:4693-4696.
29. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003;2:803-811. (Pubitemid 37361812)
30. Suzuki K, Okawara T, Higashijima T, Yokomizo K, Mizushima T, Otsuka M. Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships. Bioorganic & medicinal chemistry letters. 2005;15:2065-2068. (Pubitemid 40445470)
31. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci. 2004;5:437-448. (Pubitemid 38715511)
32. Jones KL, Krous HF, Nadeau J, Blackbourne B, Zielke HR, Gozal D. Vascular endothelial growth factor in the cerebrospinal fluid of infants who died of sudden infant death syndrome: evidence for antecedent hypoxia. Pediatrics. 2003;111:358-363. (Pubitemid 36181526)
33. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1-14. (Pubitemid 36077622)
34. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484. (Pubitemid 43199434)
35. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945. (Pubitemid 39071573)
36. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163-175. (Pubitemid 34876545)
37. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302. (Pubitemid 38991819)
38. Pause A, Belsham GJ, Gingras AC, Donzé O, Lin TA, Lawrence JC Jr, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371:762-767.